Demonstrating the utility of newly discovered drugs that induce reactivation of mutant p53 into a wild-type conformation, and the associated functional recovery of this tumor suppressor protein in cancer cells, would be necessary for the clinical translation of these drugs to treat cancers, which, in general, possess compromised p53 mediated apoptotic signaling. This evidence concerns the gene TP53 and cancer.